Molecular Templates Inc
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for th… Read more
Molecular Templates Inc - Asset Resilience Ratio
Molecular Templates Inc (MTEM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2023)
This chart shows how Molecular Templates Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Molecular Templates Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Molecular Templates Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Molecular Templates Inc Industry Peers by Asset Resilience Ratio
Compare Molecular Templates Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Molecular Templates Inc (2002–2023)
The table below shows the annual Asset Resilience Ratio data for Molecular Templates Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $35.38 Million | -- |
| 2022-12-31 | 29.58% | $28.86 Million | $97.55 Million | -31.79pp |
| 2021-12-31 | 61.37% | $118.06 Million | $192.36 Million | +12.28pp |
| 2020-12-31 | 49.09% | $68.67 Million | $139.88 Million | +26.34pp |
| 2019-12-31 | 22.75% | $39.63 Million | $174.20 Million | +15.45pp |
| 2018-12-31 | 7.30% | $10.23 Million | $140.16 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $90.39 Million | -- |
| 2016-12-31 | 53.54% | $13.00 Million | $24.28 Million | -19.30pp |
| 2015-12-31 | 72.84% | $39.09 Million | $53.67 Million | -0.57pp |
| 2014-12-31 | 73.41% | $50.21 Million | $68.40 Million | +17.33pp |
| 2013-12-31 | 56.08% | $58.39 Million | $104.12 Million | -10.74pp |
| 2012-12-31 | 66.82% | $59.82 Million | $89.52 Million | +2.60pp |
| 2011-12-31 | 64.22% | $14.41 Million | $22.44 Million | +27.14pp |
| 2010-12-31 | 37.08% | $6.01 Million | $16.20 Million | -21.22pp |
| 2009-12-31 | 58.30% | $28.38 Million | $48.69 Million | +30.29pp |
| 2008-12-31 | 28.01% | $6.87 Million | $24.53 Million | -15.72pp |
| 2007-12-31 | 43.73% | $11.29 Million | $25.81 Million | +1.02pp |
| 2006-12-31 | 42.71% | $24.36 Million | $57.03 Million | +18.51pp |
| 2005-12-31 | 24.20% | $24.71 Million | $102.10 Million | -20.27pp |
| 2004-12-31 | 44.47% | $14.33 Million | $32.21 Million | +43.97pp |
| 2003-12-31 | 0.51% | $209.00K | $41.27 Million | -0.16pp |
| 2002-12-31 | 0.67% | $45.00K | $6.73 Million | -- |